this difference was considered by the investigative
team to be an appropriate cutoff to establish
the clinical noninferiority of azithromycin to
doxycycline. It was estimated that for the study
to have 90% power to test the hypothesis at a
one-sided 0.10 significance level, the per-protocol
population would need to include 153 participants
in each group.